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P U B L I S H E D B Y E L S E V I E R I N C .CORRECTION
otan C, Meredith IT, Mauri L, Liu M, Rothman MT, for the E-Five Investigators Safety and Effectiveness
f the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice: 12-Month Data From the E-Five
egistry. J Am Coll Cardiol Intv 2009;2:1227–35.
n Table 3, the n reported in the standard-use column heading should be 2,008, not 2,125; and the n
eported in the extended-use column heading should be 5,824, not 6,189. The corrected table is printed
elow. The authors regret this error.
doi:10.1016/j.jcin.2010.01.009










Death (all) 2.4 (191) 1.2 (24) 2.9 (167) 0.001
Cardiac 1.7 (135) 0.9 (19) 2.0 (116) 0.001
MI (all) 1.6 (128) 0.7 (15) 1.9 (113) 0.001
Q-wave 0.4 (31) 0.2 (4) 0.5 (27) 0.147
Non-Q-wave 1.3 (98) 0.5 (11) 1.5 (87) 0.001
Death (cardiac)  MI (all) 3.0 (238) 1.5 (30) 1.6 (208) 0.001
ARC deﬁnite stent thrombosis 0.6 (49) 0.1 (3) 0.8 (46) 0.001
0–30 days 0.4 (28) 0.1 (2) 0.4 (26) 0.028
31–365 days 0.3 (23) 0.0 (1) 0.4 (22) 0.015
ARC deﬁnite  probable stent thrombosis 1.1 (88) 0.4 (9) 1.4 (79) 0.001
0–30 days 0.8 (59) 0.4 (8) 0.9 (51) 0.035
31–365 days 0.4 (31) 0.0 (1) 0.5 (30) 0.002
All ARC stent thrombosis 1.8 (144) 0.8 (16) 2.2 (128) 0.001
0–30 days 0.8 (59) 0.4 (8) 0.9 (51) 0.035
31–365 days 1.1 (89) 0.4 (9) 1.4 (80) 0.001
Per protocol stent thrombosis 1.0 (82) 0.4 (9) 1.3 (73) 0.001
0–30 days 0.8 (62) 0.4 (8) 0.9 (54) 0.019
31–365 days 0.3 (21) 0.0 (1) 0.3 (20) 0.024
TLR 4.5 (349) 2.8 (56) 5.0 (293) 0.001
TVR 4.9 (387) 3.0 (61) 5.6 (326) 0.001
TVR (nontarget lesion) 0.7 (52) 0.3 (6) 0.8 (46) 0.017
TVF 7.2 (565) 4.3 (87) 8.2 (478) 0.001
MACE 7.5 (587) 4.3 (87) 8.6 (500) 0.001
Values are % (n).
ARC Academic Research Consortium; MACEmajor adverse cardiac events; MImyocardial infarction; TLR target lesion revascularization; TVF target vessel failure;
TVR target vessel revascularization.
